STAT
SEPTEMBER 22, 2023
Yale and the VA agreed in 2003 to share royalties on patents with inventors from both institutions. When a comparable drug is not available, 29% turn to their pharmacy’s compounding services, while 6% look to another compounding pharmacy. Yale and professor John Krystal agreed to pay $1.5
The Checkup by Singlecare
MARCH 7, 2024
Unfortunately, a law from 2003 prohibits Medicare Part D from covering weight loss drugs, which means it won’t cover Ozempic prescribed solely for weight loss , an off-label use. Consider a compounded version Compounding pharmacies mix the active ingredients in a drug themselves.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Checkup by Singlecare
APRIL 17, 2024
Legislation passed in 2003 prohibits Medicare from covering drugs prescribed specifically for weight loss, and while Medicaid has more flexibility here, not every state will cover them. Look into compounded options (but be careful). Mounjaro’s only on-label use is for diabetes, so Medicaid likely won’t cover it for obesity.
pharmaphorum
MARCH 2, 2022
The term ‘psychedelic treatments’ incorporates a broad spectrum of different compounds, from LSD, psilocybin and DMT, to MDMA, ibogaine and ketamine. The latter compound has already been approved for treatment-resistance depression as the product Spravato (esketamine), after being developed by Janssen.
The Checkup by Singlecare
MARCH 21, 2024
A 2003 law prohibits government-sponsored plans like Medicare from covering weight loss medication. Consider a compounded version For drugs on the Food and Drug Administration (FDA) shortage list, compounding pharmacies can create and sell copies, often at lower prices than the brand-name versions.
ISPE
APRIL 13, 2023
For example, process simulators can report model-based air emissions such as volatile organic compounds (VOCs) with great accuracy since they are grounded in robust physical properties calculations, like activity coefficient models, that are embedded in the simulators. Topics in Chemical Engineering, 2003. 1 Harrison, Roger G.,
The Checkup by Singlecare
FEBRUARY 6, 2024
Since atomoxetine treats attention-deficit hyperactivity disorder by being a selective norepinephrine reuptake inhibitor and since norepinephrine is an adrenaline compound, MAOIs are hazardous if taken concurrently or within 14 days of atomoxetine. MAOIs can lead to an increase in adrenaline.
Expert insights. Personalized for you.
107 
Let's personalize your content